Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:administeredBy |
oral route
|
| gptkbp:CASNumber |
1206855-39-2
|
| gptkbp:clinicalTrialPhase |
Phase 1
|
| gptkbp:developedBy |
gptkb:Takeda_Pharmaceutical_Company
|
| gptkbp:hasMolecularFormula |
C23H22N4O2
|
| gptkbp:hasUNII |
6Q1K1Q1Q0F
|
| https://www.w3.org/2000/01/rdf-schema#label |
TAK-580
|
| gptkbp:isInvestigationalDrugFor |
gptkb:cancer
glioma |
| gptkbp:isKinaseInhibitor |
true
|
| gptkbp:IUPACName |
N-(3-(1H-imidazol-4-yl)phenyl)-6-(4-methylpiperazin-1-yl)pyrido[2,3-d]pyrimidine-7-carboxamide
|
| gptkbp:PubChem_CID |
57379313
CHEMBL2105732 |
| gptkbp:synonym |
MLN-2480
MLN2480 |
| gptkbp:target |
gptkb:RAF_kinase
|
| gptkbp:bfsParent |
gptkb:tovorafenib
|
| gptkbp:bfsLayer |
8
|